The impact of tumor heterogeneity on patient treatment decisions

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 38-40

  Farhangfar, Carol J ^a   Meric Bernstam, Funda ^a   Mendelsohn, John ^a   Mills, Gordon B ^a   Lucio Eterovic, Agda Karina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER PROGNOSIS; CLINICAL DECISION MAKING; DISEASE SEVERITY; DNA DETERMINATION; GENE EXPRESSION; HEALTH CARE COST; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; METASTASIS; MORBIDITY; SEQUENCE ANALYSIS; SHORT SURVEY; TUMOR BIOPSY;

DECISION MAKING; HUMANS; NEOPLASMS; PATIENT PARTICIPATION;

EID: 84872028705     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.194712     Document Type: Short Survey

References (5)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23- 8.
2. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805:105-17.
3. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
4. Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution inferred by single-cell sequencing. Nature 2011;472:90-4.
5. Merlo LM, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, Maley CC. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010;3:1388-97.